Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl)-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations

US9388134B2 · kind B2 · utility

Assignee

• Novartis AG · CH

Inventors

• Lili Feng · Pine Brook, US
• Sven Erik Godtfredsen · Chatham, US
• Paul Allen Sutton · Parsippany, US
• Mahavir Prashad · East Hanover, US
• Michael John Girgis · Richmond, US
• Bin Hu · Mesa, US
• Yugang Liu · Bound Brook, US
• Thomas J. Blacklock · Clark, US
• Piotr H. Karpinski · Lincoln Park, US

Key dates

• Filing date: Jun 23, 2014
• Grant date: Jul 12, 2016
• Expiry date: Jun 23, 2034

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K2300/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A method for treatment of a cardiovascular or renal condition or disease with a specific combination, linked pro-drug or a compound of an angiotensin receptor antagonist and a NEPi.